Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioSynthema Inc.
US FDA’s approval of Advanced Accelerator Applications’ radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors was driven by robust Phase III study results in midgut carcinoid tumors and data from an investigator-initiated, expanded access study in the Netherlands that enrolled patients with a host of other neuroendocrine tumor types.
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies